Эпилепсия и пароксизмальные состояния (Aug 2016)

THE COMPARATIVE EFFICACY OF PERSONALIZING THERAPY WITH ANTICONVULSANTS AND ANTIPSYCHOTICS ON THE BASIS OF PHARMACOGENETIC TESTING

  • T. V. Dokukina,
  • A. I. Startsev,
  • M. V. Makhrov,
  • I. V. Haidukevich,
  • T. S. Golubeva,
  • A. A. Gilep,
  • E. A. Sheremet,
  • I. V. Shamruk,
  • A. S. Pinchuk,
  • S. A. Marchuk,
  • F. P. Khlebokazov,
  • N. N. Misyuk

DOI
https://doi.org/10.17749/2077-8333.2016.8.2.006-013
Journal volume & issue
Vol. 8, no. 2
pp. 6 – 13

Abstract

Read online

The purpose of research — to develop a pharmacogenetic test to predict the speed and features of a metabolism of anticonvulsants, antipsychotics, antidepressants, depending on genetically determined activity of enzyme systems and proteins-transporters of drugs.Materials and Methods. During 4 years in the study included 260 patients with epilepsy and schizophrenia, located on the hospital treatment in the Centre of Mental Health (Minsk). Patients characterized by the presence of side effects and drug-resistance.Results. As a result, taking into account the genetic information in 79% of patients with epilepsy and in 73% of patients with schizophrenia, there was a significant clinical effect.Conclusion. The results demonstrated the great significance of pharmacokinetic and pharmacodynamic characteristics of the particular patient in the development of pharmacoresistance, regardless of nosology. The genetics of drug metabolism can improve the treatment and reduce the time to achieve clinical benefit from the treatment.

Keywords